Company Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction.
The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.
Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
| Country | Israel |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Motti Farbstein |
Contact Details
Address: 26 Ben Gurion Street Ramat Gan, L3 5257346 Israel | |
| Phone | 972 39241114 |
| Website | canfite.com |
Stock Details
| Ticker Symbol | CANF |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001536196 |
| CUSIP Number | 13471N201 |
| ISIN Number | US13471N3008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pnina Fishman Ph.D. | Founder, Chief Scientific Officer and Executive Chairperson |
| Motti Farbstein | Chief Executive Officer and Chief Financial and Operating Officer |
| Dr. Sari Fishman Ph.D. | Vice President of Business Development |
| Dr. Ilan Cohn Ph.D. | Co-Founder and Director |
| Dr. Stephen A. Harrison FACP, M.D. | Member of Clinical Advisory Board and Consulting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | EFFECT | Notice of Effectiveness |
| Apr 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 5, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 3, 2024 | 6-K | Report of foreign issuer |
| Mar 28, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 28, 2024 | 6-K | Report of foreign issuer |
| Mar 11, 2024 | 6-K | Report of foreign issuer |
| Feb 28, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |